Sage Therapeutics (SAGE) is laying off most of its employees after announcing its planned acquisition earlier this month, The Boston Globe’s Marin Wolf reports. The company will cut 338 jobs effective August 22, according to the report. Sage announced earlier this month that it will be acquired by Supernus Pharmaceuticals (SUPN) in a deal that could be worth up to $795M.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAGE:
- Sage Therapeutics price target lowered to $8.50 from $11 at JPMorgan
- Avidity, BridgeBio, Coty, SAGE, Alkermes: Trending by Analysts
- Sage Therapeutics price target raised to $9 from $7 at Baird
- H.C. Wainwright sees potential competition for Sage from Biogen
- Sage Therapeutics price target raised to $9 from $8 at Truist